Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BONESUPPORT HOLDING AB (publ) announces that the patient enrolment schedule for the ongoing FORTIFY study is extended

Lund, Sweden, 10.00 am CET, 21 August 2019 – BONESUPPORT™, listed on Nasdaq Stockholm - an emerging leader in orthobiologics for the management of bone voids, announces that the patient enrollment schedule for the ongoing FORTIFY study  is extended. Providing strong clinical evidence in support of its core technology, CERAMENT , is one of the cornerstones of BONESUPPORT’s strategy. The FORTIFY study was initiated in 2017 with the purpose to evaluate the safety and efficacy

Valmet to supply boiler diagnostics system to Shandong Sun Paper Industry Joint Stock Co., Ltd. in China

Valmet Furnace Imaging System [The Valmet Furnace Imaging System provides the most advanced integrated infrared (IR) imaging and temperature measurement capability for critical boiler areas.] The Valmet Furnace Imaging System provides the most advanced integrated infrared (IR) imaging and temperature measurement capability for critical boiler areas. Valmet Oyj’s trade press release on August 21, 2019 at 11:00 a.m. EET Valmet will supply boiler diagnostics system to Shandong Sun Paper Industry Joint Stock Co., Ltd. in China. The system will be installed in a new recovery boiler

EIT InnoEnergy underlines stake in Minesto becoming third largest shareholder

EIT InnoEnergy joins BGA Invest  and Midroc New Technology  as major shareholder in Minesto as it converts previously issued warrants to shares.Today, EIT InnoEnergy , the European innovation engine for sustainable energy supported by the European Institute of Innovation and Technology, has exercised warrants issued in previous years subscribing 7,121,561 shares in Minesto . This move makes EIT InnoEnergy the third largest shareholder in the Swedish marine energy developer alongside

Correction: Odfjell SE 2Q19: Improved results from Odfjell Tankers as spot and COA rates begin to recover

Odfjell SE today reported its results for the second quarter of 2019. The results reflect an improving chemical tanker spot market and improved contract renewal rates. Highlights for the second quarter of 2019: • The chemical tanker market continued to improve• EBITDA of USD 57 million, compared with USD 47 million in 1Q19• EBITDA of USD 50 million from Odfjell Tankers compared with USD 40 million in 1Q19. Excluding the effect from IFRS 16, Odfjell Tankers EBITDA improved to USD 37 million in 2Q19 vs USD 27 million in 1Q19• EBITDA of USD 6 million from Odfjell Terminals compared

Odfjell SE 2Q19: Improved results from Odfjell Tankers as spot and COA rates begin to recover

Odfjell SE today reported its results for the second quarter of 2019. The results reflect an improving chemical tanker spot market and improved contract renewal rates. Highlights for the second quarter of 2019: • The chemical tanker market continued to improve• EBITDA of USD 57 million, compared with USD 47 million in 1Q19• EBITDA of USD 50 million from Odfjell Tankers compared with USD 40 million in 1Q19. Excluding the effect from IFRS 16, Odfjell Tankers EBITDA improved to USD 37 million in 2Q19 vs USD 27 million in 1Q19• EBITDA of USD 6 million from Odfjell Terminals compared

Strong preclinical data on FG001’s potential in guiding surgical removal of pancreatic cancer has been accepted for presentation on the World Molecular Imaging Congress 2019

FluoGuide A/S’s ("FluoGuide") compound FG001 lights up the cancer and has demonstrated potential to vastly improve the radicality of surgery in preclinical studies. FG001 use is initially focused on glioblastoma, but FluoGuide is pleased to announce that data, confirming FG001’s potential in also guiding surgical removal of pancreatic cancer, will be presented at the World Molecular Imaging Congress 2019 (WMIC) in Montreal, on 4-7 September 2019.FG001 is initially focused on guiding glioblastoma surgery but has potential in several other cancer indications. One of these indications is

PRH has deregistered companies that have not filed their financial statements for registration

The Finnish Patent and Registration Office (PRH) has removed from the Finnish Trade Register ca. 3,700 limited liability companies and co-operatives that have not filed their financial statements for registration.The deregistered companies had not filed their financial statements despite reminder letters. The PRH had also informed the companies of the procedure using a number of communication channels. The companies deregistered on 19 August 2019 are listed on the prh.fi website. · Go to the website in Finnish. 

BRAbank ASA: Merger complete, focus on operational performance

Highlights: · Significant milestones reached during H1 2019 · Merger completed · Rebranding to BRAbank and IT integration on track · Successful launch of consumer finance offerings in Sweden · Equity injection of NOK 37 million completed in July · Financial results affected by significant one-offs · Write-downs NOK 30 million · Merger costs NOK 9 million · Operations · Norway: Being compliant is top priority · Finland: Solid market and improved risk selection · Sweden: Positive start up and well received in the market · Credit

NeuroVive Pharmaceutical AB Interim Report January - June 2019

Focus on genetic mitochondrial diseasesImportant events April – June · The US Food and Drug Administration, FDA, approves NeuroVive’s IND (Investigational New Drug) application, enabling clinical studies in the US with the company’s drug candidate NeuroSTAT. · The Supreme Court delivers its ruling concerning arbitration between NeuroVive and CicloMulsion AG. The Supreme Court rejects NeuroVive’s appeal. · Annual General Meeting in NeuroVive was held on 25 April in Lund. Important events after the reporting period · NeuroVive initiates second part of its ongoing KL1333

Perfadex® Plus has received patent approval in Europe

XVIVO Perfusion has received European patent approval for the company’s ready to use product Perfadex® Plus for cold preservation of lungs. Perfadex® Plus was launched in Europe and the US in 2018.As XVIVO Perfusion has previously reported, the company has developed a new ready to use version of its product for cold preservation of lungs. Patent applications for the new formulation, which is called Perfadex® Plus, have been submitted in all important markets and the European patent authority has now approved the patent in Europe. Perfadex® Plus was launched in the principal markets, the US

ORGANOCLICK AB (PUBL) PUBLISHES ITS INTERIM REPORT FOR Q2 2019

"We reached two big milestones during the second quarter. In May, our customer Fredahl Rydéns launched the burial coffin Saga based on our biocomposite OrganoComp®. The second milestone is that OrganoClick for the first time, as a listed company, reached a positive EBIT for a full quarter."  Translation from CEO Mårten Hellbergs comments to the Interim Report.   Q2, 1 April – 30 June 2019 The Group compared with 2018 » The net revenue amounted to SEK 32.71 (30.64) million » EBITDA of SEK 3.73 (0.96) million » Result before tax of SEK -0.27 (-1.08) million 1 January –

Flex LNG – AGM Notice

Flex LNG Limited (the “Company”) announces that its 2019 Annual General Meeting will be held on September 13, 2019. A copy of the Notice of Annual General Meeting and associated information including the Company`s Consolidated Financial Statements for 2018 can be found in the links below and on our website at www.flexlng.com.    August 21, 2019 The Board of Directors Flex LNG Limited Hamilton, Bermuda      This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act or the Continuing Obligations of Oslo Børs.

Storytel enters into a new agreement with Bonnierförlagen

Storytel Sweden AB (“Storytel”) has today entered into a three-year term agreement with Bonnierförlagen. This means that Storytel’s approximately 400,000 Swedish customers once again will have access to the full catalogue of Bonnierförlagen, including new releases, from 1 September 2019.Storytel has since 1 April 2019 not been able to offer new releases from Bonnierförlagen due to a disagreement between the parties as to content of a new cooperation agreement. Today, a new three-year term agreement has been entered into, meaning that Storytel’s Swedish customers again will be able to

ZICCUM AB Half Year Report Q2 2019

Summary of Half Year Report second quarter 2019: This has been an eventful year for Ziccum.Summary of Half Year Report, second quarter 2019 2019 has been eventful for Ziccum: We have filed a patent application for an important component in the development of new vaccines, Adenovirus. This has resulted in several industrial players showing new interest in our technology. We also announced that we have entered into a Contract Research agreement with one of these companies, aimed at evaluating LaminarPace ™ in combination with their own project. In the second quarter we also got together

Presentation of the Q2 report

Oslo, Norway (21 August 2019) A presentation will be held via webcast at 10 am CET, Wednesday 21stAugust 2019, followed by a Q&A session. Please follow the below link to join the webcast; https://webtv.hegnar.no/presentation.php?webcastId=98042744 For more information, please contact: Kjetil Ramsøy CEO, NattoPharma E-mail: kjetil.ramsoy@nattopharma.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Aker Solutions to Deliver Umbilicals for the Dalma Gas Development Project in the United Arab Emirates (UAE)

August 21, 2019 - Aker Solutions has won an order from ADNOC (Abu Dhabi National Oil Company) to deliver subsea umbilicals for the Dalma gas development project located offshore UAE in the shallow waters of the Persian Gulf. "This is the first subsea umbilical award by ADNOC in the UAE and the first subsea award for Aker Solutions in the Persian Gulf," said Luis Araujo, chief executive officer of Aker Solutions. "We are very pleased with the opportunity to further develop our relationship with ADNOC and to demonstrate our umbilical capabilities in the region." The value of the

Cxense ASA announces second quarter and first half 2019 results

Oslo, Norway - 21 August 2019 - Cxense ASA today reported financial results for the second quarter and first half ending 30 June 2019. Highlights: - Received offer from Piano (event after reporting period) ·Voluntary cash offer at NOK 16 per share ·Unanimously recommended by BoD and management ·Pre-accepted by 53% of outstanding shares, including shares of BoD and management - Continue executing on strategic plan ·Customer touchpoints and product development capacity to increase as new sales, customer success, engineering and data science resources are

Update on the Phase III NEPTUNE trial

21 August 2019 07:00 BST Update on the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer AstraZeneca today announced final overall survival (OS) results from the Phase III NEPTUNE trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) in combination with tremelimumab, an anti-CTLA4 antibody, vs. standard-of-care (SoC) platinum-based chemotherapy in previously-untreated Stage IV (metastatic) non-small cell lung cancer (NSCLC) patients. The trial was performed in an all-comers population, and the primary analysis

Hansa Biopharma to participate in three upcoming investor conferences

Hansa Biopharma has been invited to participate in three global biotech and healthcare conferences during September including Goldman Sachs’ Biotech Symposium in London, Morgan Stanley’s Global Healthcare conference in New York City and Bank of America Merrill Lynch Global Healthcare Conference in LondonLund, Sweden August 21, 2019. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company’s management team will participate in the following upcoming investor conferences: · The Goldman Sachs Ninth Annual Biotech

OssDsign AB (publ) publishes Q2 2019 interim report

OssDsign CEO Anders Lundqvist: “Overall this has been an historic quarter for OssDsign – one in which we became a public company and in which we have taken further control of the key markets for our future growth. Our present financial position and ongoing organizational developments will allow us to capitalize on the multiple substantial opportunities for growth.”The second quarter in figures: · Net sales amounted to TSEK 3 454 (2 908). · Loss after taxes amounted to TSEK 18 330 (14 324). · Loss per share was SEK 1.3 (3.0). · Cash flow from current operations was TSEK -13 917

New forecast: Global turbulence to hit Swedish growth

Growth in the Swedish economy is now so slow that we can refer to it as a full-on deterioration, reports Handelsbanken in its new Global Macro Forecast. “We foresee a cooling-off, and expect the Riksbank to keep the repo rate negative for several years to come”, says the bank’s Chief Economist, Christina Nyman.During the summer, the trade war between the US and China has escalated, while the risk of a hard Brexit is increasing. Nothing points to a quick solution, and the major global uncertainty is set to persist, according to Handelsbanken’s forecast. “Naturally, central banks, led by

GROSS PROFIT GROWTH OF 14 PERCENT, GROWTH ON ALL MARKETS

This is a translation of the Swedish interim report. If there should be any discrepancies, the Swedish language version governs. SECOND QUARTER, APRIL – JUNE 2019 · Net sales increased by 9.1% to MSEK 70.8 (64.9) · Gross profit increased 13.8% to MSEK 55.5 (48.8) · EBIT was MSEK -0.4 (-1.2) · Earnings after tax was MSEK -0.4 (-1.7) · Earnings per share was, basic SEK -0.05 (-0.24), diluted SEK -0.05 (-0.23) FIRST HALF YEAR, JANUARY – JUNE 2019  · Net sales increased by 12.0% to MSEK 137.1 (122.5) · Gross profit increased by 16.3% to MSEK 106.4 (91.5) · EBIT

NattoPharma continues growth in the second quarter

Oslo, Norway (21 August 2019) NattoPharma increased revenues by 10% in the second quarter and 22% for the first half of the year. Adjusted EBITA in the quarter came in at NOK 0,9 million, yet another profitable quarter for the company. CEO, Kjetil Ramsøy: “We continue to deliver growth with first half year revenues of NOK 58 million, representing an increase of more than 22% on the same period in 2018, and another quarter with a positive EBITDA line. At the same time, we have made pleasing progress with our new ingredient with positive results from the studies that have been

Alimak Group: Interim report January – June 2019

Solid Group performance, mixed outcomes within the business areas · Order intake decrease mainly stemming from weak development in Construction Equipment. Another all-time high of orders in a quarter for After Sales · Strong revenue growth in Construction Equipment compensates slight decrease in Industrial Equipment · Margin improvement both year-over-year and sequentially for the Group, EPS increase of 37% Second quarter · Order intake decreased by 3% to MSEK 1,150 (1,182) with an organic decrease of 7% · Revenue grew by 7% to MSEK 1,193 (1,112) with an organic

There are no items matching the current filter
There are no more items matching the current filter
Back to top